Proximagen is based on the expertise of Professor Peter Jenner, one of the world's leading authorities on neuro-degenerative diseases. It provides drug discovery services to pharmaceutical companies with R&D programmes in Parkinson's disease and other neurodegenerative disorders and has also initiated a number of proprietary drug discovery programmes.
Since formation, Proximagen's order book has expanded rapidly and the Company now has significant contracts, predominantly with international pharmaceutical customers.
As at 30 June 2011 |
|---|
IP Group holding |
|
8.4% |
|
Holding represents undiluted beneficial equity interest excluding debt